| D006973 |
Hypertension |
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. |
Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures |
|
| D009543 |
Nifedipine |
A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. |
Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS |
|
| D002121 |
Calcium Channel Blockers |
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. |
Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium |
|
| D003692 |
Delayed-Action Preparations |
Dosage forms of a drug that act over a period of time by controlled-release processes or technology. |
Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations |
|
| D004232 |
Diuretics |
Agents that promote the excretion of urine through their effects on kidney function. |
Diuretic,Diuretic Effect,Diuretic Effects,Effect, Diuretic,Effects, Diuretic |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D001581 |
Benzothiadiazines |
Heterocyclic compounds of a ring with SULFUR and two NITROGEN atoms fused to a BENZENE ring. Members inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS and are used as DIURETICS. |
|
|
| D049993 |
Sodium Chloride Symporter Inhibitors |
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA. |
Benzothiadiazine Diuretic,Potassium Depleting Diuretic,Sodium Chloride Cotransporter Inhibitor,Sodium Chloride Symporter Inhibitor,Thiazide Diuretic,Thiazide Sensitive NaCl Cotransporter Inhibitor,Benzothiadiazine Diuretics,Diuretics, Thiazide,Potassium Depleting Diuretics,Sodium Chloride Cotransporter Inhibitors,Thiazide Diuretics,Thiazide Sensitive NaCl Cotransporter Inhibitors,Depleting Diuretic, Potassium,Diuretic, Benzothiadiazine,Diuretic, Potassium Depleting,Diuretic, Thiazide,Diuretics, Benzothiadiazine,Diuretics, Potassium Depleting |
|